Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: An important factor for evasion from negative growth control

Laboratory Investigation

Volumn 79, Issue 12, 1999, Pages 1521-1534

  Gerharz, Claus D ^a   Ramp, Uwe ^a   Déjosez, Marion ^a   Mahotka, Csaba ^a   Czarnotta, Beate ^a   Bretschneider, Ute ^a   Lorenz, Ingrid ^a   Müller, Martina ^b   Krammer, Peter H ^c   Gabbert, Helmut E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

APOPTOSIS; ARTICLE; CANCER CELL; FLOW CYTOMETRY; GROWTH REGULATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALIGNANT TRANSFORMATION; MEMBRANE BINDING; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTIGENS, CD95; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL DIVISION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MEMBRANE GLYCOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 19244376868     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Boonstra JG, van der Woude FJ, Wever PC, Laterveer JC, Daha MR, and van Kooten C (1997). Expression and function of Fas (CD95) on human renal tubular epithelial cells. J Am Soc Nephrol 8:1517-1524.
2. Caignard A, Guillard M, Cai C, Asselin-Paturel C, Carayol G, and Chouaib S (1996). The renal cell carcinoma lysis by a specific cytotoxic T cell clone is independent of the Fas/ Fas-L cytotoxic pathway. Tissue Antigens 48:295-300.
3. Cascino I, Fiucci G, Papoff G, and Ruberti G (1995). Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154:2700-2713.
4. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, and Mountz JD (1994). Protection from Fasmediated apoptosis by a soluble form of Fas molecule. Science 263:1759-1762.
5. Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, and Feldman M (1991). Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51:6372-6380.
6. Friesen C, Herr I, Krammer PH, and Debatin KM (1996). Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 2:574-577.
7. Friesen C, Fulda S, and Debatin KM (1997). Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia 11:1833-1841.
8. Fulda S, Sieverts H, Friesen C, Herr I, and Debatin KM (1997). The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 57:3823-3829.
9. Fulda S, Los M, Friesen C. and Debatin KM (1998). Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 76:105-114.
10. Gerharz CD, Moll R, Störkel S, Ramp U, Thoenes W, and Gabbert HE (1993). Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro. Am J Path 142:851-858.
11. Gerharz CD, Moll R, Störkel S, Ramp U, Hildebrandt B, Molsberger G, Koldovsky P, and Gabbert HE (1995). Establishment and characterization of two devergent cell lines derived from a human chromophobe renal cell carcinoma. Am J Pathol 146:953-961.
12. Gerharz CD, Hildebrandt B, Moll R, Ramp U, Sarbia M, Störkel S, Koldovsky P, and Gabbert HE (1996). Chromophilic renal cell carcinoma: cytomorphological and cytogenetic characterisation of four permanent cell lines. Br J Cancer 74:1605-1614.
13. Heaney ML and Golde DW (1996). Soluble cytokine receptors. Blood 87:847-857.
14. Hetts SW (1998). To die or not to die. An overview of apoptosis and its role in disease. JAMA 279:300-307.
15. Horie S, Kano M, Higashihara E, Moriyama N, Tanaka E, Hirose A, Kakizoe T, and Kawabe K (1997). Expression of Fas in renal cell carcinoma. Jpn J Clin Oncol 27:384-388.
16. Krams SM, Fox CK, Beatty PR, Cao S, Villanueva JC, Esquivel CO, and Martinez OM (1998). Human hepatocytes produce an isoform of Fas that inhibits apoptosis. Transplantation 65:713-721.
17. Krigel RL, Padavic-Shaller KA, Rudolph AR, Konrad M, Bradley EC, and Comis RL (1990). Renal cell carcinomas: treatment with recombinant interleukin-2 plus beta-interferon. J Clin Oncol 8:460-467.
18. Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, and Möller P (1993). Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415-429.
19. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, and Debatin KM (1997). Cross-resistance of CD95-and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 90:3118-3129.
20. Mikisch G, Röhrich K, Kössig J, Forster S, Tschada R, and Alken P (1990). Mechanisms and modulation of multidrug-resistance in primary human renal cell carcinoma. J Urol 144:755-759.
21. Miyake H, Hara I, Gohji K, Arakawa S, and Kamidono S (1998). p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. Int J Oncol 12:469-473.
22. Mosman T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65:55-64.
23. Müller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, and Galle PR (1997). Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99:403-413.
24. Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, and Krammer PH (1998). p53 activates the CD95 (APO-1/ Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 11:2033-2045.
25. Nagata S and Golstein P (1995). The Fas death factor. Science 267:1449-1455.
26. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, and Kratzke RA (1997). Human lung carcinomas express Fas ligand. Cancer Res 57:1007-1012.
27. Nonomura N, Miki T, Yokoyama M, Imazu T, Takada T, Takeuchi S, Kanno N, Nishimura K, Kojima Y, and Okuyama A (1996). Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Biochem Biophys Res Com 229:945-951.
28. Olive C, Cheung C, Nicol D, and Falk MC (1999). Expression of apoptosis regulatory molecules in renal cell carcinoma: elevated expression of Fas ligand. Immunol Cell Biol 77:11-18.
29. Palmer PA, Vinke I, Evers P, Pourreau C, Oskam R, Roest G, Vlems F, Becker L, Loriaux E, and Franks CR (1992). Continous infusion of recombinant interleukin-2 with or without autologous activated killer cells for the treatment of advanced renal cell carcinoma. Eur J Cancer 28A:1038-44.
30. Peduto-Eberl, Guillou L, Saraga E, Schroter M, French LE, Tschopp J, and Juillerat-Jeanneret L (1999). Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas. Int J Cancer 81:772-8.
31. Peter ME, Dhein I, Ehret A, Helbardt S, Walczak H, Moldenhauer G, and Krammer PH (1995). APO-1 (CD95)-dependent and independent antigen-receptor-induced apoptosis in human T and B cell lines. Int Immunol 7:1873-1877.
32. 1 resistance: An important progression factor in human renal cell carcinoma. Lab Invest 76:739-749.
33. Ramp U, Jaquet K, Reinecke P, Schardt C, Friebe U, Nitsch T, Marx N, Gabbert HE, and Gerharz CD (1997b). Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J Urol 157:2345-2350.
34. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, and Bennink JR (1993). Identification of human cancers deficient in antigen processing. J Exp Med 177:265-272.
35. Roman S, Petrusca D, Moldovan I, Paraoan M, Petrescu A, Damian D, Noica N, and Sulica A (1999). Evaluation of apoptosis of tumor and of apparently normal cells in human renal carcinoma. Immunol Lett 67:15-22.
36. Schneider P, Holler N, Bodnier JL, Hahne M, Frei K, Fontana A, and Tschopp J (1998). Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187:1205-1213.
37. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, and Peter ME (1998). Apoptosis signaling by death receptors. Eur J Biochem 254:439-459.
38. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, and Galle PR (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: A mechanism of immune evasion? Nature Med 2:1361-1366.
39. Sträter I, Mariani SM, Walczak H, Rücker FG, Leithäuser F, Krammer PH, and Möller P (1999). CD95 ligand (CD95L) in normal human lymphoid tissues. A subset of plasma cells are prominent producers of CD95L. Am J Pathol 154:193-201.
40. Sugahara K, Yamada Y, Hiragata Y, Matsuo Y, Tsuruda K, Tomonaga M, Maeda T, Atogami S, Tsukasaki K, and Kamihira S (1997). Soluble and membrane isoforms of Fas/CD95 in fresh adult T-Cell leukemia (ATL) cells and ATL-cell lines, Int J Cancer 72:128-132.
41. Tanaka M, Itai T, Adachi M, and Nagata S (1998). Downregulation of Fas ligand by shedding. Nature Med 4:31-36.
42. Tomita Y, Kawasaki T, Bilim V, Takeda M, and Takahashi K (1996). Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/APO-1 (CD95)-mediated apoptosis in renal-cell-cancer cells. Int J Cancer 68:132-135.
43. Traut BC, Klas C, Peters AM, Matzku S, Möller P, Falk W, Debatin KM, and Krammer PH (1989). Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-305.
44. von Rheyer U, Sträter J, Kittstein W, Gschwendt M, Krammer PH, and Möller P (1998). Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res 58:526-534.
45. Weller M, Malipiero U, Aguzzi A, Reed JC, and Fontana A (1995). Protooncogene bcl-2 gene transfer abrogates Fas/ APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95:2633-2643.